Patients with hypersensitivity to adrenomimetics should use Ginipral® in small doses prescribed individually, under the constant supervision of a physician.
Before starting treatment with Ginipral®, ECG monitoring should be performed.
During the period of treatment with Ginipral®, periodic monitoring of the ECG, pulse and blood pressure in the mother, and the heart rate of the fetus are necessary. When the mother's heart rate rises (more than 130 beats / min) or with significant fluctuations in blood pressure, the dose of the drug should be reduced.
When pain occurs in the heart (including compressive, angina), difficulty breathing and signs of heart failure, Ginipral® is immediately withdrawn and ECG monitoring is performed.
Initial hypokalemia should be corrected before treatment drugs kyattiya If the birth took place immediately after Ginipralom® treatment, newborns need to conduct a survey to identify hypoglycemia and acidosis (blood pH).
In patients with diabetes mellitus during the treatment with Ginipral®, regular monitoring of the glucose concentration in the blood plasma is necessary.
Clinical signs of premature placental abruption against the background of tocolytic therapy with Ginipral® may be less pronounced.
With prolonged tocolytic therapy, it is necessary to check the condition of the fetoplacental system using standard methods of investigation.
If the integrity of the bladder is compromised and the cervix is opened more than 2-3 cm, the effectiveness of tocolytic therapy is unlikely.
During the period of treatment with Ginipral®, excessive fluid intake should be avoided, as diuresis decreases under the influence of the drug. It should be carefully monitored for symptoms that reflect fluid retention in the body (swelling of the legs, shortness of breath), especially with simultaneous treatment with glucocorticosteroids and with concomitant diseases that contribute to fluid retention (kidney disease, gestosis, proteinuria and hypertension). It is necessary to reduce salt intake. The daily intake of liquid should not exceed 2 liters. If there are signs of fluid retention and symptoms of pulmonary edema (cough, shortness of breath), the drug should be discarded.
During tocolytic therapy with Ginipral®, regularity of the stool should be monitored, the drug suppresses the intestinal peristalsis.
If halothane anesthesia is planned, therapy with Ginipral® should be discontinued. If an operative intervention is necessary, the anesthetist should be informed of the therapy with Ginipral®.
Tokoliticheskaya therapy with beta-adrenomimetics can strengthen the symptoms of the present dystrophic myotonia. In such cases, the administration of phenytoin is recommended.
It is necessary to take into account the intake of any other drugs in case of Ginipral® therapy.
Caffeine-containing drinks (including coffee and tea) can enhance the side effects of Ginipral®.
If there are side effects or conditions related to contraindications, it is necessary to inform the doctor.